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Peptidomics techniques have identiﬁed hundreds of peptides that are derived from proteins
present mainly in the cytosol, mitochondria, and/or nucleus; these are termed intracellular
peptides to distinguish them from secretory pathway peptides that function primarily out-
side  of the cell. The proteasome and thimet oligopeptidase participate in the production and
metabolism of intracellular peptides. Many of the intracellular peptides are common among
mouse tissues and human cell lines analyzed and likely to perform a variety of functions
within cells. Demonstrated functions include the modulation of signal transduction, mito-
chondrial stress, and development; additional functions will likely be found for intracellular
peptides.ell signaling
eptidomics
rotein–protein interaction
eceptors
© 2014 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). 
peptide until it is either the correct length and able to bind to
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.  Historical  perspectives
ver since the discovery of the proteasome, a multisubunit
omplex that converts proteins into peptides, it was recog-
ized that peptides would transiently exist inside of cells
Fig. 1). The formation and degradation of intracellular pep-
ides is as complex as the production and degradation of
icroRNA (Fig. 1). Intracellular peptides typically range in size
rom 2 to 21 amino acids, with the average size of the protea-
ome degradation products 10–12 amino acids in length [1].
he conventional view is that the proteasome-produced pep-
ides are rapidly broken down by cytosolic aminopeptidases
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212-9685 © 2014 The Authors. Published by Elsevier B.V. on behalf ofwith a half life of several seconds [2,3]. Some of the pep-
tides produced by the proteasome are protected from cytosolic
aminopeptidases by transport into the endoplasmic reticulum
(ER) by a peptide transporter. Once in the ER, if the peptide is
the correct size and contains the appropriate amino acids in
key positions, the peptide binds to major histocompatibility
complex I (MHC-I) and is transported to the cell surface where
it serves in antigen presentation [2]. If the peptide is too long
to bind to MHC-I, an ER resident aminopeptidase trims ther for Research in Proteolysis and Cell Signaling (NAPPS), Room 315,
restes 1524, São Paulo, SP 05508-000, Brazil. Tel.: +55 11 30917493.
bert Einstein College of Medicine, 1300 Morris Park Avenue F248,
einstein.yu.edu (L.D. Fricker).
MHC-I, or if unable to bind to MHC1, the aminopeptidase con-
tinues until the peptide is degraded. Ultimately, only a very
small fraction of intracellular peptides (e.g. one peptide of 9–11
 European Proteomics Association (EuPA). Open access under CC BY-NC-ND license.
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Fig. 1 – Comparison of the key steps in the formation and degradation of microRNA and intracellular peptides. Micro RNA
(miRNA) is produced from primary transcripts (pri-mRNA) by a series of nucleases: Drosha, Pasha, and Dicer. Once the
miRNA duplexes dissociate to form the miRNA, it is able to form an RNA-induced silencing complex that contains many
associated proteins including members of the argonaute protein family. Degradation of miRNA–RNA complex is mediated by
ribonucleases. Intracellular peptides are primarily produced by the proteasome although other proteases such as calpains,
caspases, and mitochondrial enzymes are also known to generate intracellular peptides. There are several intracellular
peptidases that cleave moderately sized peptides, which are not able to directly cleave proteins. These oligopeptidases
include endopeptidase 24.15 (also known as thimet oligopeptidase), neurolysin (also known as endopeptidase 24.16),
insulin-degrading enzyme, prolyl oligopeptidase, and nardilysin. These enzymes have different substrate speciﬁcities such
that they each produce distinct patterns of intracellular peptides from the proteasome-produced peptides. There is evidence
that some of the intracellular peptides are biologically active. Final degradation of the intracellular peptides is mediated by
aminopeptidases, including tripeptidyl peptidase II, leucine aminopeptides, puromycin-sensitive aminopeptidase, and
bleomycin hydrolase. In addition to the formation of intracellular peptides from proteins, it is also possible that intracellular
adinpeptides are produced directly from RNA with short open re
amino acids for each protein) end up on cell surface, and until
recent peptidomics analyses detected a large number of intra-
cellular peptides (described below), only a small number of
intracellular peptides were known.
One of the best-studied intracellular peptides is the yeast
Saccharomyces cerevisiae a-factor, which functions as a mating
pheromone [4]. Yeast has two peptide mating factors, named
alpha-factor and a-factor. Alpha-factor is produced within the
secretory pathway, much like mammalian peptide hormones
(although with different processing enzymes), stored in vesi-
cles, and secreted when the vesicles fuse with the cellular
membrane. In contrast, a-factor is produced within the cytosol
by a series of steps involving lipid attachment (prenylation),
N-terminal proteolytic cleavages by Ste24p and Axl1p, and
transport from the cytosol to the extracellular space by Ste6p
[4]. The secreted a-factor binds to a speciﬁc receptor (Ste3p)
and stimulates mating.
Despite the precedence for cytosolic peptides function-
ing in plasma membrane receptor-mediated cell-cell signaling
that was provided from studies on yeast a-factor, there has
been resistance to the idea that mammalian cells signalg frames [74,75] or from defective ribosome products [76].
each other using peptides produced from cytosolic pro-
teins. Some peptides were isolated from mammalian brains
based on bioactive properties, but when these molecules
were found to represent fragments of intracellular proteins,
there was little enthusiasm amongst the scientiﬁc commu-
nity. Examples of bioactive peptides from cytosolic proteins
include diazepam binding inhibitor (DBI) from acyl-coA bind-
ing protein and hippocampal cholinergic neurostimulating
peptide (HCNP) from phosphatidylethanolamine-binding pro-
tein [5–7]. During the 1980s and 1990s while the above studies
were on-going, a number of cellular endopeptidases were dis-
covered and characterized (Fig. 1). Some of these enzymes,
such as endopeptidase 24.15 (also named endo-oligopeptidase
A and thimet oligopeptidase), are able to convert neuro-
peptides into smaller fragments; in some cases this conversion
causes the neuropeptide to be inactive, while in other cases
the product is also biologically active but with differing recep-
tor speciﬁcity [8–11]. In the latter cases, the endopeptidase
was thought to play a modulatory role, rather than simply
activating or inactivating the peptide. While the extracellu-
lar processing of neuropeptides may represent a bona ﬁde
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acids, but shorter peptides. Degradation of the peptides ise u  p a o p e n p r o t e o m i
unction for endopeptidase 24.15 and related enzymes, the
nding that the vast majority of the enzyme is present in
he cytosol and/or nucleus suggested other functions for these
nzymes [12]. One suggested function was in the processing
f peptides post-proteasome for eventual binding to MHC-I, as
art of the antigen presentation machinery [13]. However, the
ubstrate speciﬁcity did not entirely ﬁt with this scheme, as
he majority of MHC-I antigens evaluated in vitro were not good
ubstrates of endopeptidase 24.15 [14]. Thus, the function of
ndopeptidase 24.15 and related intracellular oligopeptidases
as not clear, and a logical function would be a role in the post-
roteasome processing of intracellular peptides that served as
ignaling molecules within cells (Fig. 1) [15]. The intracellular
eptides bear a resemblance to microRNAs that are produced
y selective intracellular enzymes and ultimately regulate pro-
ein function (Fig. 1).
.  Peptide  and  protein  interactions  in  cell
ommunication
any  studies have used synthetic peptides to perturb cel-
ular functions. For example, peptides capable of inhibiting
he interactions between kinases and their anchoring proteins
16] were rationally designed, synthesized and shown to regu-
ate kinase-mediated functions [17,18]. Kaneto and co-workers
emonstrated that c-Jun N-terminal kinase is inhibited by
 peptide derived from a kinase-interacting protein, preven-
ing the access of the kinase to its substrate c-Jun [19]. When
 cell-permeable version of this peptide was injected into
ice, a signiﬁcant improvement in insulin resistance was
bserved, with consequent improvement of glucose tolerance,
n a model of type 2 diabetes. Peptides derived from A-kinase
nchoring protein have been used to alter subcellular local-
zation of protein kinase A [20]. A peptide named inhibitory
eptide, was characterized as a highly potent and speciﬁc
ubstrate competitive inhibitor of Calmodulin-Dependent Pro-
ein Kinase II [21], which plays important roles in controlling
 variety of cellular functions in the Central Nervous Sys-
em [22,23]. All of these studies used synthetic peptides, and
lthough the sequences were based on protein sequences, it
as not thought that these peptides (or similar ones) existed
n vivo.
Endogenous bioactive peptides have been shown to play
 role in the maintenance of mitochondrial protein stability
24]. In mitochondria, proteases degrade proteins into pep-
ides that are exported from the mitochondrial matrix into the
ntermembrane space by ABC transporters and reach the cyto-
ol by passive diffusion. Recently, Haynes et al. demonstrated
y genetic analysis of Caenorhabilis elegans that under stress
f mitochondrial protein misfolding, signals are emitted from
he mitochondrial matrix to the nucleus by the bZIP protein,
hich regulates nuclear-encoded mitochondrial chaperone
enes [24]. Consequently, the organelle can react against the
oss of thermodynamic stability and the propensity of proteins
o aggregate. Note that this response includes expression of nuclear-encoded protein gene termed ubiquitin-like ClpXP.
lpXP is activated by a homeobox containing the transcrip-
ion factor bZIP, which in turn, is supposed to be activated
y a pathway that involves different peptides produced by ( 2 0 1 4 ) 143–151 145
ATP-dependent Clp proteases. The combined expression of
these proteins represents the cell response toward the damage
produced by irreversible aggregates and protein misfolding
affecting cell functions and survival. In general, this response
is elicited to maintain protein homeostasis by increasing the
expression of heat shock proteins (chaperones) to assist the
process of protein folding. Signal peptides generated by the
mitochondrial ATP-dependent proteolytic complex can acti-
vate the cell genome, providing a mechanism of intercellular
communication among mitochondria, cytosol and nucleus
[24].
3.  Intracellular  proteolytic  generation  of
peptides
In eukaryotic cells, most proteins destined for degradation
are initially tagged with a polyubiquitin chain in an energy-
dependent process, and then digested to peptides by the 26S
proteasome, a large proteolytic complex involved in the regu-
lation of cell division, gene expression and other key processes
[25–27]. In one study it was estimated that in eukaryotes, the
proteasome converts 30–90% of newly synthesized proteins
into peptides within minutes [28]. Therefore, the concomitant
action of proteasomes and other proteolytic systems [29,30] in
the cytosol, nucleus and mitochondria suggests a continuous
formation and release of peptides within cells [2,31,32].
Following the proteasome, peptides can be further cleaved
by cytosolic oligopeptidases (Fig. 1). Over the past decades,
many  peptidases have been isolated and characterized [33–39].
Although most of these enzymes are present in the extracel-
lular medium—an essential prerequisite for their association
to the physiological metabolism of neuropeptides—many of
them predominate in the intracellular milieu. Some of the
intracellular enzymes can process both proteins and peptides.
For example, tripeptidyl-peptidase II primarily cleaves three
amino acid residues from the N-terminal of peptides/proteins,
and also functions as an endopeptidase [35,39,40]. Sev-
eral other cytosolic endopeptidases are known for their
selectivity for oligopeptides and inability to directly cleave
proteins into peptides. Examples include insulin-degrading
enzyme (IDE), endopeptidase 24.15 (thimet oligopeptidase),
endopeptidase 24.16 (neurolysin), and prolyl oligopeptidase
[33,34,36–38,41,42]. Although oligopeptidases are not likely to
initiate cleavages of proteins due to their restrictions on sub-
strate size, such enzymes contribute to the production of
peptides from intermediates generated by the proteasome
system or other intracellular proteases.
The various cytosolic oligopeptidases do not appear to be
degradative enzymes, but instead have fairly limited sub-
strate speciﬁcities. For example, endopeptidase 24.15 is able
to cleave only a subset of the peptides present in the cytosol;
some are much better substrates than others [38]. Further-
more,  the products of the oligopeptidases are not aminocarried out by aminopeptidases that convert the peptides
into amino acids (Fig. 1). Several cytosolic aminopeptidases
are known, including leucine aminopeptidase, puromycin-
sensitive aminopeptidase, and bleomycin hydrolase [43,44].
 m i c s
a subset of the peptides detected in the tissue was found146  e u  p a o p e n p r o t e o
4.  Identiﬁcation  of  intracellular  peptides
For a long time it was believed that all peptides generated in
cytosol, nucleus and/or mitochondria were quickly hydrolyzed
to amino acids, and reused in the synthesis of new proteins
and/or metabolic intermediates [2,3]. However, development
of a “substrate capture assay” that used point mutations
for inactivating the catalytic site of oligopeptidases allowed
identiﬁcation of several peptides derived from intracellular
proteins in the rat brain [45]. In parallel, the development
of mass spectrometry-based peptidomic techniques made it
possible to identify the most abundant peptides present in a
tissue, cell line, or other biological sample, without the use of
the substrate capture assay. Initial studies examining extracts
of rodent brain identiﬁed hundreds of peptides, most of which
were subsequently found to represent postmortem degrada-
tion [46]. This postmortem change could be prevented by rapid
heating of the brain tissue, either by microwave irradiation or
by rapid removal of the tissue and heating prior to dissection
into regions [46–49]. Another problem was the degradation of
proteins and peptides during the extraction process. Many of
the early studies on neuropeptides used hot acid to extract
the peptides but for peptidomics this was found to induce
the cleavage of bonds adjacent to aspartate residues, with
aspartyl–prolyl bonds especially sensitive to hot acid [50]. The
postmortem and extraction artifacts could be prevented by
heat inactivation of the brain tissue followed by extraction
in ice-cold acid, thus allowing the detection of many  neuro-
peptides in addition to intracellular peptides [50]. Altogether,
the use of the substrate capture assay and the development
of modern mass spectrometry techniques revealed the pres-
ence of a large number of peptides derived from intracellular
proteins that escape further degradation [51].
Currently, more  than 400 intracellular peptides have been
identiﬁed in several human cell lines and mouse tissue
extracts [51–54]. Although some of the precursor proteins of
these peptides are commonly found in the cytosol, mitochon-
dria and/or nucleus, only a few of them correspond to the most
abundant proteins in a cell [53,55]. Moreover, only some of
the protein precursors of intracellular peptides display high
turnover rates [53,56] or ubiquitin labels [57]. Taken together,
these ﬁndings indicate that the precursor proteins of intracel-
lular peptides are not the most rapidly degraded proteins in
the cells.
Because the majority of the intracellular peptides detected
in extracts of human cell lines or mouse tissues are not derived
from the most abundant or most unstable proteins, it is pos-
sible that these peptides are produced from selective cleavage
of proteins. In addition to the proteasome, intracellular pro-
teases such as caspases and calpains can execute limited
cleavages of proteins such as hemoglobin. However, the speci-
ﬁcity of caspases for cleavage sites containing aspartic acid
does not ﬁt with the sequences of the assessed intracellular
peptides since most of the peptides are produced by cleav-
ages at hydrophobic residues. Moreover, it is unlikely that
calpain contributes to the production of intracellular pep-
tides based on the ﬁnding that activation of this enzyme (by
treating cells with a calcium ionophore) did not affect the lev-
els of intracellular peptides [53]. Recently, it was shown that 3 ( 2 0 1 4 ) 143–151
treatment of cells with a proteasome inhibitor (epoxomicin)
greatly decreases the levels of most intracellular peptides,
thus conﬁrming that the proteasome is the major source of
production of these peptides [58]. However, it is not known if
the proteasome-mediated generation of the intracellular pep-
tides is part of the degradation pathway of the proteins, or if
this reﬂects a more  selective processing step. For example, the
proteasome can perform limited cleavages of proteins such as
NF-kappaB [59].
5.  Intracellular  peptides  and  cell
communication
Because the intracellular peptides do not generally reﬂect the
degradome of the cell, it is likely that they are produced for a
purpose. Furthermore, as described above, synthetic peptides
introduced into cells can perform a variety of functions. There-
fore, it is likely that the endogenous intracellular peptides are
able to perform the same functions that have been found for
synthetic peptides (Fig. 2), either outside or inside the cell.
Functions outside of the cell include roles as intercellular
messengers, like classic neuropeptides that are produced in
the secretory pathway and secreted upon stimulation. For this
to occur, the intracellular peptides would need to be secreted
from the cell and then interact with another cell in a way that
affected the cell’s function. A precedent for this type of activ-
ity is yeast a-factor, mentioned above. Intracellular peptides
found in mouse brain (and other tissues) that appear to func-
tion in cell-cell communication include the hemopressins, a
family of related peptides produced from alpha- and beta-
hemoglobin. The original hemopressin peptide is a 9-residue
peptide fragment of alpha-hemoglobin, which was found to be
an antagonist/inverse agonist of the CB1 cannabinoid recep-
tor. N-terminally extended forms of 11 and 12 residues were
subsequently identiﬁed and found to have agonistic and nega-
tive allosteric properties on CB1 [60,61] these longer forms may
represent the major forms of hemopressin peptides in brain.
Although many  people consider hemoglobin to be a blood cell-
speciﬁc protein, it is expressed in a number of different cell
types, including neurons and glia [62,63]. The 12-residue form
of hemopressin was recently found to be secreted from brain
slices, supporting the proposed role for this peptide in inter-
cellular signaling [64]. A number of other intracellular peptides
and proteins are known to be secreted, including some inter-
leukins, growth factors, cytokines, and other molecules [65].
The mechanisms by which this secretion occurs have not
been fully elucidated, and this is an important area for further
research.
6.  Intracellular  peptides  and  the
modulation  of  signal  transduction
In a recent study of peptides secreted from brain slices, onlyto be secreted from the cells, and the majority of the pep-
tides were not secreted [64]. Thus, it is likely that intracellular
peptides are functional within the cell. Several possible roles
have been proposed. One of these roles isin the modulation
e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 143–151 147
Fig. 2 – Potential functions for endogenous peptides. In all of the examples shown, the peptide is indicated in red. (A)
Peptide binds to receptor, functions as agonist, antagonist, or allosteric modulator. Classical neuropeptides are generally
receptor agonists. Peptides that are produced in the cytosol and secreted can also bind to receptors, as in the case of the
hemopressin peptides, which function as CB1 cannabinoid receptor agonists or antagonists/inverse agonists depending on
the length of the peptide [60]. Intracellular peptides that are not secreted may potentially bind to cysotolic domains on
receptors and alter signaling. (B) Peptide binds to active site or allosteric site of enzyme and alters activity. Examples of
enzymes inhibited by endogenous peptides include proprotein convertase 2 [77], proprotein convertase 1 [78], neprilysin
[79], and insulin-regulated aminopeptidase [80]. In these examples, the peptide binds to the active site and causes the
enzyme to be inactive, as shown in the ﬁgure. Many  other enzymes have been found to be inhibited by synthetic peptides,
raising the possibility that intracellular peptides perform this function. It is also possible that a peptide binds to an
allosteric site and activates the enzyme (not shown in ﬁgure). (C) Peptide binds to protein and modiﬁes the ability of the
protein to interact with other proteins. Many  proteins form multimers that affect the properties of the protein, and synthetic
peptides have been used to disrupt these interactions and alter the protein’s function [81]. In some cases, the synthetic
peptides activate the protein by mimicking the effect of the protein–protein interaction, in other cases the peptides inhibit
the protein by blocking the protein–protein interaction. It is possible that endogenous peptides perform similar functions as
found for synthetic peptides. (D) Peptide binds to protein and alters intramolecular folding. Many  proteins undergo
conformational changes that alter the protein’s function, and synthetic peptides have been used to alter these changes by
binding preferentially to one state of the folded protein [82]. It is possible that endogenous peptides perform similar
functions. (E) Peptide binds to protein and alters its targeting. Synthetic peptides have been used to alter the distribution of
a protein through a combination of the above (altering protein–protein interactions and/or protein folding), or through
another mechanism, such as blocking the interaction of a protein with a membrane or other intracellular molecule [20]. (F):
Peptide binds to protein and blocks its degradation. It is possible that the interaction of a peptide and protein alters the
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margeting of the protein to lysosomes or to the proteasome, tf post-translational modiﬁcations. The majority of the pep-
ides detected using the substrate capture assay described
bove have at least one potential site for post-translational
odiﬁcation, raising the possibility that these peptides couldby affecting protein degradation.be natural competitors of protein phosphorylation [15,66]. In
addition, Machado and co-workers demonstrated in vitro that
phosphorylation of peptides changed their metabolic rates
by endopeptidase 24.15 and neurolysin, which should change
 m i c s148  e u  p a o p e n p r o t e o
their susceptibility to peptidase degradation [67]. Accordingly,
to test their biological activity three intracellular peptides
were chosen based on the presence of a protein kinase C
(PKC) phosphorylation site and on their binding to the cat-
alytically inactive endopeptidase 24.15 using the substrate
capture assay. When these peptides were applied externally
to cells, they were not able to change signaling by G protein-
coupled receptors (GPCRs) but when the same peptides were
attached to a cell-penetrating peptide (CPP), the peptides syn-
ergistically modulated angiotensin II and isoproterenol signal
transduction in HEK293 and CHO cells [68]. Of the three pep-
tides tested, two of them could be phosphorylated by PKC.
Considering that all three peptides modiﬁed angiotensin II-
induced or isoproterenol-induced luciferase expression in
the same fashion, it became clear that phosphorylation of
PKC is not the general mechanism responsible for the effect
of peptides on the increase in luciferase expression. Even
though the mechanism was not known, these studies pro-
vided the ﬁrst evidence that natural intracellular peptides
identiﬁed using the substrate capture assay could directly
affect GPCRs signal transduction from inside the cells. Over-
expression of endopeptidase 24.15, which was shown to
change the intracellular peptidome in HEK293 cells, increased
the transcription of luciferase in HEK293 and CHO-S cells
stimulated by GPCR agonists angiotensin II or isoproterenol,
supporting the hypothesis that intracellular peptides modu-
late signal transduction [68]. Recently, it has been shown that
cell signaling stimulated by isoproterenol can be enhanced by
means of siRNA inhibition of endopeptidase 24.15, which in
parallel altered the intracellular peptidome of HEK293 cells
[69]. Inhibition of protein kinase A abolished the synergic
effect of endopeptidase 24.15 siRNA treatment on isopro-
terenol signaling, further suggesting a role of intracellular
peptides in signal transduction [69]. Under this scenario, intra-
cellular oligopeptidases such as endopeptidase 24.15 play an
important role in regulating the half life of their substrates or
peptide products, with the potential to alter the signal trans-
duction cascade and corresponding cellular functions without
further energy consumption [38].
Using the substrate capture assay, Heimann et al. demon-
strated that high-fat diet-fed mice bearing three functional
copies of Ace gene produced intracellular peptides of lower
molecular weight, when compared to high-fat diet-fed mice
bearing a single copy of Ace gene [66]. In addition, those
animals containing three copies of the Ace gene showed a
signiﬁcant improvement in insulin sensitivity when com-
pared to the control group. Treatment of mice with losartan
(angiotensin II receptor antagonist) had no effect on weight
gain or on the development of insulin resistance, suggesting
that alternative mechanisms involving intracellular content
of peptides may be related to an improvement of insulin
resistance observed in those animals [66]. Semi-quantitative
liquid chromatographic mass spectrometric (LC/MS/MS) anal-
ysis have been used for determination of intracellular peptide
content in adipose tissue of rats fed with a hypercaloric
western diet [70]. The intracellular levels of two out of ten
intracellular peptides, found in the epididymal adipose tissue
of animals, were at least two times higher in rats fed with the
hypercaloric diet when compared to the control group. These
two peptides signiﬁcantly increased glucose uptake if added 3 ( 2 0 1 4 ) 143–151
back into 3T3-L1 adipocytes [70]. These results support ear-
lier ﬁndings [66] suggesting that intracellular peptides from
adipocytes may regulate insulin signal transduction and glu-
cose uptake [70]. Therefore, intracellular peptides were shown
to modulate signal transduction of both GPCRs and tyrosine
kinase receptors.
7.  Potential  roles  for  intracellular  peptides
in the  modulation  of  protein  interactions
In addition to a competitive action on protein phosphory-
lation, a possible general mechanism by which intracellular
peptides affect signal transduction is through the modulation
of protein interactions (Fig. 2). To search for proteins that inter-
act with intracellular peptides, several peptides that affect
GPCR signal transduction were immobilized and used for afﬁn-
ity chromatography [68]. Several proteins that interact with
the intracellular peptides were detected, including dynamin,
2-adaptin, and 14-3-3; all of these proteins are involved in
cell signaling [71,72]. 2-adaptin is the major component of
protein complexes that link clathrin to receptors in coated
vesicles, and for this reason, it is directly involved in GPCRs
internalization [72]. Although many  other proteins were found
to bind to the immobilized peptide afﬁnity columns, it is
unlikely that all of them bind directly to these peptides. Sec-
ondary interactions of protein are probably responsible for the
large number of proteins identiﬁed [68]. Moreover, two  pep-
tides that were found to increase glucose uptake by 3T3-L1
adipocytes were also shown to interact with speciﬁc proteins
[70]. One of these proteins, annexin 6, bound only to one of
these peptides, whereas heat shock protein 8 was identiﬁed
as a ligand of both peptides in the extracts from the adi-
pose tissues of rats fed with a Western diet but not in rats
fed the control non-caloric diet [70]. A recent study demon-
strated that peptides FE2 and FE3 among others can modulate
either positively or negatively the formation of protein com-
plexes related to Ca-calmodulin and 14-3-3 epsilon [73]. The
peptide VFD7, a proteasome product derived from the S100
calcium-binding protein, is one of the intracellular peptides
that efﬁciently (at 1–10 M) inhibited the interaction between
Ca2+-calmodulin and endopeptidase 24.15 [73]. Using isotope
labeling semi-quantitative mass spectrometry it was possible
to determine the intracellular concentration of VFD7 within
HEK293 cells to be in the order of 16 M [73]. When VFD7 was
added back into the HEK293 cells it enhanced intracellular cal-
cium levels, a similar role of its precursor S100 protein [73].
This ﬁnding suggests the exciting possibility that intracellu-
lar peptides can modulate speciﬁc protein interactions within
cells. Further studies are necessary to investigate the in vivo
effect of intracellular peptides in protein network regulation.
8.  Summary  and  further  directions
There are many  similarities between intracellular peptides
and microRNA. Generation of microRNA and intracellular pep-
tides both requires enzymatic processing starting from a long
molecule to produce smaller ones with the same chemical
nature that regulate cell function (Fig. 1). The mechanism of
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icroRNA allows cells to regulate with great speciﬁcity RNA
tability and as a consequence the synthesis of speciﬁc pro-
eins can be controlled. Within the cells, intracellular peptides
ave been suggested to regulate signal transduction [68,69],
itochondrial protein stability [24], enhance intracellular cal-
ium levels [73] and stimulate glucose uptake [70]. Interaction
f intracellular peptides with proteins is likely the mechanism
ehind their functions both inside and outside the cell (for
hose peptides that are secreted). However, it is very likely
hat additional functions will be found for the intracellular
eptides.
There are still a number of unanswered questions about
ntracellular peptides function and metabolism that require
dditional research. One important area is to identify the
nzymes that generate and degrade the intracellular peptides,
nd to determine how these processes are regulated. Although
he proteasome has been implicated in the biosynthesis of
ost of the intracellular peptides observed in cell lines, based
n the effect of proteasome inhibitors on the levels of these
eptides, some of the intracellular peptides are not greatly
ffected by the proteasome inhibitors and therefore are likely
o be produced by alternative mechanisms. Little is known
egarding the mechanisms of degradation of the intracellular
eptides and the regulation of the synthetic and degrada-
ive steps. Another important area is to determine which of
he intracellular peptides are secreted, the mechanism of this
ecretion, and if this process is regulated. If the intracellular
eptides function as non-classical neuropeptides, then either
heir production or secretion should be regulated. Similarly, if
he intracellular peptides modulate protein function, then the
evels of the intracellular peptides should be regulated under
arious physiological and pathological conditions.
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